Mizuho Securities Reiterates Buy on Ventas (VTR) Ahead of 3Q Report
- Indexes hit record highs as Trump rally continues
- Lower for longer, ECB scales back asset buys
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Oil rises above $50 on renewed hopes for output cuts
- LPL Financial (LPLA) Said to Decide to Stay Independent After Reviewing Options - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Mizuho Securities reiterated a Buy rating and $84.00 price target on Ventas (NYSE: VTR) ahead of the company's 3Q earnings report. The company took a $700mm loan to help finance Ardent's purchase of LHP. VTR's key focal point with regard to its fledgling hospital platform is market share, and estimates Ardent's at 25%-50% and LHP's at upwards to 60%. The loan is the first follow-on hospital investment since the August 2015 Ardent deal.
Analyst Richard Anderson commented, "We will be reviewing our model following 3Q16, including the accretive impact from higher interest income ($700mm @ 8% initially, growing with LIBOR, and a five-year term). However, we see that as a short-term benefit only that doesn't necessarily sway REIT investors. The size of Ardent Health Services would grow by about 50%, from 14 to 19 hospitals, with the planned merger with LHP Hospital Group. As such, a few things could materialize longer-term as VTR propagates its hospital agenda, such as broadening VTR's hospital rolodex (including several notfor-profits that are participants in existing joint ventures on the five real estate assets currently owned by LHP). Not-for-profits make up the vast majority of US hospitals, so this is important stepping stone for any new entrant into the hospital business. VTR also has first rights on the LHP hospitals, but it is complicated at the moment by the aforementioned joint ventures. Even further out, protecting the Ardent balance sheet could be a precursor to a future IPO, thereby broaden VTR's net of influence and relationships. So we think VTR is making the loan commitment (along with a stamp of approval vis-à-vis an undisclosed equity investment from Sam Zell's EGI) to open up a variety of potential future outcomes."
Shares of Ventas closed at $68.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Cuts Price Target on SecureWorks Corp. (SCWX) to $13
- MKM Partners Raises Price Target on Ollie's Bargain Outlet (OLLI) Following 3Q
- BMO Capital Reiterates Market Perform on Casey's General Stores (CASY) Following 2Q Report
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesSam Zell, Earnings, Definitive Agreement, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!